Literature DB >> 11727176

Implant contraception.

K R Meckstroth1, P D Darney.   

Abstract

The experience of 6 million Norplant users has led to several more advanced implants. Implanon is a single-rod implant system containing a low androgenic progestin and requires 1 to 2 minutes for insertion and removal. Like other implants, Implanon prevents pregnancy by changing the character of the cervical mucus and interfering with luteal function. Unlike Norplant, though, Implanon is designed to prevent ovulation for the full duration of use. Implant contraception has several advantages over other types of contraception including high efficacy, minimal required maintenance, absence of estrogen, and rapid return of fertility after discontinuation. Implants can be a good choice for adolescents; women with hypertension, diabetes, anemia, endometriosis, or other medical problems; and women who are breast-feeding. Irregular bleeding is the most common adverse effect of implants and can be treated with several medication regimens. Preinsertion counseling, however, is the most important factor in ensuring satisfaction with implants. Unfortunately, no implant system is currently available in the United States since August 2000, but Implanon is expected to reach the U.S. market within the next 2 years.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11727176     DOI: 10.1055/s-2001-18642

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  3 in total

Review 1.  Contraception across transgender.

Authors:  Ilaria Mancini; Stefania Alvisi; Giulia Gava; Renato Seracchioli; Maria Cristina Meriggiola
Journal:  Int J Impot Res       Date:  2021-02-08       Impact factor: 2.896

2.  Haematological and biochemical effects of etonogestrel subdermal implant (Implanon) in Ilorin Nigeria.

Authors:  Olayinka R Balogun; Abiodun S Adeniran; Adebayo A Adewole
Journal:  Int J Health Sci (Qassim)       Date:  2016-10

Review 3.  Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.

Authors:  Irving Sivin
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.